Related Experiment Videos
Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells
W Dichtl1, L Nilsson, I Goncalves
1Wallenberg Laboratory, Department of Medicine, University of Lund, Malmö University Hospital, Malmö, Sweden. wolfgang.dichtl@medforsk.mas.lu.se
Circulation Research
|May 15, 1999
Summary
High levels of Very Low-Density Lipoprotein (VLDL) activate nuclear factor-kappaB (NF-kappaB), a key inflammation factor. This VLDL-induced activation, mediated by fatty acids, promotes atherosclerosis development.
Area of Science:
- Cardiovascular Biology
- Molecular Inflammation
- Atherosclerosis Research
Background:
- High plasma Very Low-Density Lipoprotein (VLDL) levels are linked to increased atherosclerosis risk.
- Nuclear Factor-kappaB (NF-kappaB) is a critical transcription factor in inflammatory pathway regulation.
Purpose of the Study:
- To investigate the role of VLDL in activating NF-kappaB.
- To elucidate the mechanisms by which VLDL influences arterial inflammation and atherosclerosis.
Main Methods:
- In vitro activation assays of NF-kappaB by VLDL and its components.
- In vivo studies involving intravenous VLDL injection in rats.
- Assessment of arterial NF-kappaB activation using electrophoretic mobility shift assay.
- Analysis of adhesion molecule and cytokine expression in aortic endothelial cells.
Main Results:
- VLDL activates NF-kappaB in a concentration-dependent manner.
- Free fatty acids released from VLDL, not VLDL oxidation, mediate NF-kappaB activation.
- In vivo VLDL administration induced arterial NF-kappaB activation and expression of inflammatory markers.
- Antioxidant probucol did not inhibit VLDL-induced NF-kappaB activation.
Conclusions:
- VLDL promotes atherosclerosis by activating the pro-inflammatory transcription factor NF-kappaB.
- The mechanism involves VLDL-derived fatty acids and contributes to arterial inflammation.
- These findings highlight VLDL's role in the inflammatory processes underlying atherosclerosis.